Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accounts Payables (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Accounts Payables for 11 consecutive years, with $14000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 97.9% year-over-year to $14000.0, compared with a TTM value of $14000.0 through Dec 2025, down 97.9%, and an annual FY2025 reading of $14000.0, down 97.9% over the prior year.
  • Accounts Payables was $14000.0 for Q4 2025 at Spyre Therapeutics, down from $7.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $16.6 million in Q4 2023 and bottomed at $14000.0 in Q4 2025.
  • Average Accounts Payables over 5 years is $3.5 million, with a median of $2.9 million recorded in 2022.
  • The sharpest move saw Accounts Payables soared 2349.63% in 2023, then plummeted 97.9% in 2025.
  • Year by year, Accounts Payables stood at $3.3 million in 2021, then crashed by 79.6% to $677000.0 in 2022, then skyrocketed by 2349.63% to $16.6 million in 2023, then plummeted by 95.98% to $666000.0 in 2024, then tumbled by 97.9% to $14000.0 in 2025.
  • Business Quant data shows Accounts Payables for SYRE at $14000.0 in Q4 2025, $7.5 million in Q3 2025, and $3.7 million in Q2 2025.